This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with a broad impact on public health as it accounts for approximately 13% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. A major focus of recent lung cancer research has been the development and subsequent approval of a number of molecular-targeted agents and the identification of related biomarkers to help guide treatment selection for patients with specific oncogenic alterations. Although the advent of these targeted treatments promises both efficacy and enhanced safety in the management of lung cancer, it also challenges practicing oncologists to appropriately select individuals who may benefit from these agents. In addition, clinical oncologists need to determine how to integrate such therapies into standard lung cancer treatment algorithms as they become available. Although several consensus- and evidence-based treatment guidelines are available to assist clinicians in making lung cancer treatment decisions, many areas of controversy persist in the academic and community settings. This CME program brings together leading clinical investigators and general oncologists to provide biological insights into the use of biomarkers and targeted therapy for patients with lung cancer. By reviewing the available clinical trial data and relevant case scenarios, this initiative will address gaps in medical knowledge and illuminate treatment ambiguities.
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Program: Research To Practice designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 2.75 (audio) and 3.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BiomarkersLung20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/BiomarkersLung20/Video.
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BiomarkersLung20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/BiomarkersLung20.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Justin F Gainor, MD
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy, Termeer Center for Targeted Therapies
Massachusetts General Hospital
Assistant Professor, Harvard Medical School
Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Takeda Oncology, Tesaro, A GSK Company.
Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
Advisory Committee: AstraZeneca Pharmaceuticals LP, BeyondSpring Inc, Bristol-Myers Squibb Company, Inivata; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.
Geoffrey R Oxnard, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Dropworks, Foundation Medicine, GRAIL, Guardant Health, Illumina, Inivata, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Sysmex Corporation, Takeda Oncology; Contracted Research: GRAIL.
Heather Wakelee, MD
Professor of Medicine, Division of Oncology
Faculty Director, Stanford Cancer Clinical Trials Office
Stanford University School of Medicine
Stanford Cancer Institute
Consulting Agreements: Cellworks, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Helsinn Group, Janssen Biotech Inc, Merck, Mirati Therapeutics, Xcovery; Contracted Research: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Pfizer Inc, Xcovery.
Isaac Levy, MD
Memorial Healthcare System
No financial interests or affiliations to disclose.
Estelamari Rodriguez, MD, MPH
Associate Director for Community Outreach-Thoracic Oncology
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Advisory Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Genentech, a member of the Roche Group.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Lilly and Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: May 2020
Expiration date: May 2021
After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.